Bdenza-OS

Bdenza-OS is a brand name for Enzalutamide 32 mg Oral Solution, which is a medication used to treat certain types of prostate cancer. Here are some key points about the product:

Composition:

Enzalutamide 32 mg Oral Solution is a clear, colorless liquid containing enzalutamide, a non-steroidal anti-androgen.

Indications:

Enzalutamide 32 mg Oral Solution is indicated for the treatment of:

1. Metastatic castration-resistant prostate cancer (mCRPC) in patients who have previously received androgen-deprivation therapy (ADT)
2. Metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen-deprivation therapy

Mechanism of Action:

Enzalutamide 32 mg Oral Solution works by:

1. Binding to androgen receptors in the body, preventing them from being activated by androgens
2. Inhibiting the growth and proliferation of prostate cancer cells

Dosage and Administration:

The recommended dosage of Enzalutamide 32 mg Oral Solution is:

• 32mg taken orally once daily, with or without food
• Take at the same time each day

Side Effects:

Common side effects of Enzalutamide 32 mg Oral Solution include:

1. Fatigue
2. Back pain
3. Nausea
4. Headache
5. Constipation
6. Hot flashes
7. Musculoskeletal pain

Serious side effects can include:

1. Seizures or convulsions
2. Psychiatric events (e.g., depression, anxiety, insomnia)
3. Cardiac arrhythmias
4. Hepatotoxicity (e.g., liver damage)

Contraindications:

Enzalutamide 32 mg Oral Solution is contraindicated in patients with:

1. Hypersensitivity to enzalutamide
2. Pregnancy or breastfeeding (unless absolutely necessary)
3. Severe hepatic impairment (Child-Pugh C)

Precautions:

1. Patients with a history of seizure disorders or convulsions should be closely monitored while receiving Enzalutamide 32 mg Oral Solution.
2. Patients with a history of cardiac disease or cardiac dysfunction should be closely monitored while receiving Enzalutamide 32 mg Oral Solution.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of seizures or convulsions.
• Patients should be advised to report any changes in their appetite, nausea, or vomiting.

Storage and Handling:

• Store vials at room temperature between 15°C and 30°C (59°F and 86°F).
• Do not expose to direct sunlight or moisture.
• Use within 24 hours of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.